Vascular Biogenics Ltd. Stock News

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VB L Therape u tics  (Nasdaq: VBLT ), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant

TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced that the independent Data Safety Monitoring Committee (DSMC) of the ongoing OVAL Phase 3 registrati

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences:

Vascular Biogenics recently resumed dosing American patients in its OVAL Phase 3 trial.

TEL AVIV, Israel, Aug. 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced enrollment of new patients in VB-111 studies in the Unites States will resume immediately following

Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Conference Call and Webcast at 8:30 a.m. EDT Today

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before mar

TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT).

VBL Therapeutics recently announced that they were allowed to add progression-free survival as a second primary endpoint for VB-111's Phase III OVAL study in ovarian cancer. The addition of the PFS en